시장보고서

상품코드

1493251

세계의 폐암 액체 생검 시장 규모, 점유율, 동향 분석 보고서 : 샘플 유형별, 바이오마커별, 기술별, 최종 용도별, 임상 용도별, 제품별, 지역별, 부문 예측(2024-2030년)

Lung Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report By Sample Type, By Biomarker, By Technology, By End-use, By Clinical Application, By Product, By Region, And Segment Forecasts, 2024 - 2030

발행일: 2024년 05월 | 리서치사:

Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

폐암 액체 생검 시장의 성장과 동향 :

Grand View Research, Inc의 최신 보고서에 따르면 세계 폐암 액체 생검 시장 규모는 2024년부터 2030년까지 13.3%의 연평균 복합 성장률(CAGR)로 성장하여 2030년에는 23억 5,000만 달러에 달할 것으로 예측됩니다.

액체 생검은 기존의 조직 생검을 대체하는 비침습성을 제공하여 폐암의 조기 발견을 가능하게 합니다. 진단 업계는 정확하고 종합적인 진단 도구가 필요한 정밀의료를 향하고 있습니다. 액체 생검는 개인화된 치료 계획에 대한 정보를 제공하는 유망한 솔루션입니다.

발견 지연이나 높은 사망률 등의 요인에 의해 전체 생존율은 저하하고 있습니다. 담배의 흡연과 담배에 대한 노출과 같은 생활 습관은 심각한 위험 요인의 일부이며 세계 폐암 환자 전체의 약 80%에 기여하고 있습니다. 세계보건기구(WHO)에 따르면 2020년에는 세계 인구의 22.3%가 담배를 소비하고 있으며, 이는 남성의 36.7%, 여성의 7.8%를 차지합니다. 또 담배는 추정 130만명의 수동흡연자를 포함해 매년 800만명 이상의 사인이 되고 있다고 합니다.

기업은 폐암을 스크리닝하는 새로운 기술과 제품을 출시하고 있습니다. 예를 들어, Delfi Diagnostics는 2023년 10월에 폐암을 스크리닝하는 혈액 검사를 출시했습니다. 이러한 새로운 출시와 함께 출시 증가는 시장을 추진할 것으로 예상됩니다.

폐암 리퀴드 생검 시장 보고서 하이라이트

샘플 유형에 따라 혈액 샘플 기반 부문이 2023년 시장을 독점했습니다. 이는 이 샘플 유형의 비침습성, 재현성, 실시간 모니터링 기능, 조기 발견, 비용 효과에 기인합니다.
바이오마커에 근거하여, 순환 핵산 분절은 암이 조기 단계에 있더라도 혈액 샘플에서 매우 낮은 농도에서 검출할 수 있기 때문에 2023년 시장을 선도했습니다.
기술별로 다 유전자 병렬 분석(NGS) 분야가 2023년 시장을 독점했습니다.
폐암 유병률 증가, 라이프스타일 변화, 헬스케어 진보, 상환정책 이용 가능성 등의 요인으로 인해 2023년 폐암 액체 생검 시장은 북미가 지배적이었습니다.
예를 들어 American Cancer Society Journals에 따르면 2022년에는 미국에서 약 1,918,030명의 새로운 암 사례가 관찰되었으며, 이는 암 사망의 주요 원인인 폐암에 의한 매일 약 350명의 사망을 포함 되었습니다.

주요 시장 진출기업에 의한 최근의 동향과 영향 분석
기업/경쟁의 분류
벤더 상황
기업 프로파일
- Agilent Technologies Inc.
- Bio-Rad Laboratories, Inc.
- CARDIFF ONCOLOGY, INC.
- CareDx
- Eurofins Scientific
- Exact Sciences Corporation
- F. Hoffmann-La Roche Ltd
- Guardant Health
- Illumina, Inc.
- LungLife AI, Inc.
- Myriad Genetics, Inc.
- Natera, Inc.
- QIAGEN
- Thermo Fisher Scientific Inc.

JHS 24.06.20

Lung Cancer Liquid Biopsy Market Growth & Trends:

The global lung cancer liquid biopsy market size is anticipated to reach USD 2.35 billion by 2030, growing at a CAGR of 13.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. Liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, enabling earlier detection of lung cancer. The diagnostics industry is moving towards precision medicine, which requires accurate and comprehensive diagnostic tools. Liquid biopsies offer a promising solution for providing information for personalized treatment plans.

Factors such as late detection and high mortality rates result in a decline in the overall survival rate. Lifestyle habits such as cigarette smoking and tobacco exposure are some of the significant risk factors, contributing to approximately 80% of the total lung cancer cases worldwide. According to the World Health Organization (WHO), in 2020, 22.3% of the world's population consumed tobacco, which constitutes 36.7% of men and 7.8% of the total women. It also states that tobacco causes the deaths of more than 8 million people each year, including an estimated 1.3 million passive smokers.

Companies are launching newer technologies and products to screen lung cancers. For instance, Delfi Diagnostics launched its blood test to screen for lung cancer in October 2023. This increasing number of launches involving newer launches is anticipated to propel the market.

Lung Cancer Liquid Biopsy Market Report Highlights:

Based on sample type, the blood sample-based segment dominated the market in 2023. This can be attributed to the non-invasive nature, repeatability, real-time monitoring capabilities, early detection, and cost-effectiveness of this sample type.
Based on biomarker, the circulating nucleic acids segment led the market in 2023 as it can be detected at very low concentrations in blood samples, even when cancer is at an early stage.
Based on technology, the multi-gene-parallel analysis (NGS) segment dominated the market in 2023.
North America dominated the market for lung cancer liquid biopsy in 2023, owing to factors such as the increasing prevalence of lung cancer, changes in lifestyles, advancements in healthcare, and availability of reimbursement policies.
For instance, according to the American Cancer Society Journals, in 2022, approximately 1,918,030 new cancer cases were observed in the U.S., which included approximately 350 deaths each day from lung cancer, the leading cause of cancer death.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Sample Type
- 1.2.2. Biomarker
- 1.2.3. Technology
- 1.2.4. End-use
- 1.2.5. Clinical Application
- 1.2.6. Product
- 1.2.7. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Sample Type Outlook
- 2.2.2. Biomarker Outlook
- 2.2.3. Technology Outlook
- 2.2.4. End-use Outlook
- 2.2.5. Clinical Application Outlook
- 2.2.6. Product Outlook
2.3. Competitive Insights

Chapter 3. Lung Cancer Liquid Biopsy Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
3.3. Lung Cancer Liquid Biopsy Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape

Chapter 4. Lung Cancer Liquid Biopsy Market: Sample Type Estimates & Trend Analysis

4.1. Sample Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Lung Cancer Liquid Biopsy Market by Sample Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.4.1. Blood Sample Based
  - 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.2. Others
  - 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Lung Cancer Liquid Biopsy Market: Biomarker Estimates & Trend Analysis

5.1. Biomarker Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Lung Cancer Liquid Biopsy Market by Biomarker Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.4.1. Circulating Nucleic Acids
  - 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.2. CTC
  - 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.3. Exosomes/Microvesicles
  - 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.4. Circulating Proteins
  - 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Lung Cancer Liquid Biopsy Market: Technology Estimates & Trend Analysis

6.1. Technology Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Lung Cancer Liquid Biopsy Market by Technology Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.4.1. Multi-gene-parallel Analysis (NGS)
  - 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.2. Single Gene Analysis (PCR Microarrays)
  - 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Lung Cancer Liquid Biopsy Market: End-use Estimates & Trend Analysis

7.1. End-use Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Lung Cancer Liquid Biopsy Market by End-use Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 7.4.1. Hospitals and Laboratories
  - 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.2. Specialty Clinics
  - 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.3. Academic and Research Centers
  - 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.4. Others
  - 7.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Lung Cancer Liquid Biopsy Market: Clinical Application Estimates & Trend Analysis

8.1. Clinical Application Market Share, 2023 & 2030
8.2. Segment Dashboard
8.3. Lung Cancer Liquid Biopsy Market by Clinical Application Outlook
8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 8.4.1. Therapy Selection
  - 8.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.2. Treatment Monitoring
  - 8.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.3. Early Cancer Screening
  - 8.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.4. Recurrence Monitoring
  - 8.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.5. Others
  - 8.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Lung Cancer Liquid Biopsy Market: Product Estimates & Trend Analysis

9.1. Product Market Share, 2023 & 2030
9.2. Segment Dashboard
9.3. Lung Cancer Liquid Biopsy Market by Product Outlook
9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 9.4.1. Instruments
  - 9.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.2. Consumables Kits and Reagents
  - 9.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.3. Software and Services
  - 9.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Lung Cancer Liquid Biopsy Market: Region Estimates & Trend Analysis

10.1. Regional Market Share, 2023 & 2030
10.2. Lung Cancer Liquid Biopsy Market by Region Outlook
10.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
- 10.3.1. North America
  - 10.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.1.2. U.S.
  - 10.3.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.1.3. Canada
  - 10.3.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 10.3.2. Europe
  - 10.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.2.2. UK
  - 10.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.2.3. Germany
  - 10.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.2.4. France
  - 10.3.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.2.5. Italy
  - 10.3.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.2.6. Spain
  - 10.3.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.2.7. Denmark
  - 10.3.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.2.8. Sweden
  - 10.3.2.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.2.9. Norway
  - 10.3.2.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 10.3.3. Asia Pacific
  - 10.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.3.2. Japan
  - 10.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.3.3. China
  - 10.3.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.3.4. India
  - 10.3.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.3.5. Thailand
  - 10.3.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.3.6. South Korea
  - 10.3.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.3.7. Australia
  - 10.3.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 10.3.4. Latin America
  - 10.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.4.2. Brazil
  - 10.3.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.4.3. Mexico
  - 10.3.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.4.4. Argentina
  - 10.3.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 10.3.5. Middle East and Africa
  - 10.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.5.2. South Africa
  - 10.3.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.5.3. Saudi Arabia
  - 10.3.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.5.4. UAE
  - 10.3.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.3.5.5. Kuwait
  - 10.3.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

11.1. Recent Developments & Impact Analysis, By Key Market Participants
11.2. Company/Competition Categorization
11.3. Vendor Landscape
- 11.3.1. List of key distributors and channel partners
- 11.3.2. Key customers
- 11.3.3. Key company heat map analysis, 2023
11.4. Company Profiles
- 11.4.1. Agilent Technologies Inc.
  - 11.4.1.1. Company overview
  - 11.4.1.2. Financial performance
  - 11.4.1.3. Product benchmarking
  - 11.4.1.4. Strategic initiatives
- 11.4.2. Bio-Rad Laboratories, Inc.
  - 11.4.2.1. Company overview
  - 11.4.2.2. Financial performance
  - 11.4.2.3. Product benchmarking
  - 11.4.2.4. Strategic initiatives
- 11.4.3. CARDIFF ONCOLOGY, INC.
  - 11.4.3.1. Company overview
  - 11.4.3.2. Financial performance
  - 11.4.3.3. Product benchmarking
  - 11.4.3.4. Strategic initiatives
- 11.4.4. CareDx
  - 11.4.4.1. Company overview
  - 11.4.4.2. Financial performance
  - 11.4.4.3. Product benchmarking
  - 11.4.4.4. Strategic initiatives
- 11.4.5. Eurofins Scientific
  - 11.4.5.1. Company overview
  - 11.4.5.2. Financial performance
  - 11.4.5.3. Product benchmarking
  - 11.4.5.4. Strategic initiatives
- 11.4.6. Exact Sciences Corporation
  - 11.4.6.1. Company overview
  - 11.4.6.2. Financial performance
  - 11.4.6.3. Product benchmarking
  - 11.4.6.4. Strategic initiatives
- 11.4.7. F. Hoffmann-La Roche Ltd
  - 11.4.7.1. Company overview
  - 11.4.7.2. Financial performance
  - 11.4.7.3. Product benchmarking
  - 11.4.7.4. Strategic initiatives
- 11.4.8. Guardant Health
  - 11.4.8.1. Company overview
  - 11.4.8.2. Financial performance
  - 11.4.8.3. Product benchmarking
  - 11.4.8.4. Strategic initiatives
- 11.4.9. Illumina, Inc.
  - 11.4.9.1. Company overview
  - 11.4.9.2. Financial performance
  - 11.4.9.3. Product benchmarking
  - 11.4.9.4. Strategic initiatives
- 11.4.10. LungLife AI, Inc.
  - 11.4.10.1. Company overview
  - 11.4.10.2. Financial performance
  - 11.4.10.3. Product benchmarking
  - 11.4.10.4. Strategic initiatives
- 11.4.11. Myriad Genetics, Inc.
  - 11.4.11.1. Company overview
  - 11.4.11.2. Financial performance
  - 11.4.11.3. Product benchmarking
  - 11.4.11.4. Strategic initiatives
- 11.4.12. Natera, Inc.
  - 11.4.12.1. Company overview
  - 11.4.12.2. Financial performance
  - 11.4.12.3. Product benchmarking
  - 11.4.12.4. Strategic initiatives
- 11.4.13. QIAGEN
  - 11.4.13.1. Company overview
  - 11.4.13.2. Financial performance
  - 11.4.13.3. Product benchmarking
  - 11.4.13.4. Strategic initiatives
- 11.4.14. Thermo Fisher Scientific Inc.
  - 11.4.14.1. Company overview
  - 11.4.14.2. Financial performance
  - 11.4.14.3. Product benchmarking
  - 11.4.14.4. Strategic initiatives

세계의 폐암 액체 생검 시장 규모, 점유율, 동향 분석 보고서 : 샘플 유형별, 바이오마커별, 기술별, 최종 용도별, 임상 용도별, 제품별, 지역별, 부문 예측(2024-2030년)

Lung Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report By Sample Type, By Biomarker, By Technology, By End-use, By Clinical Application, By Product, By Region, And Segment Forecasts, 2024 - 2030

폐암 액체 생검 시장의 성장과 동향 :

폐암 리퀴드 생검 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 폐암 액체 생검 시장의 변수, 동향, 범위

제4장 폐암 액체 생검 시장 : 샘플 유형의 추정 및 동향 분석

제5장 폐암 액체 생검 시장 : 바이오마커의 추정 및 동향 분석

제6장 폐암 액체 생검 시장 : 기술 추정 및 동향 분석

제7장 폐암 액체 생검 시장 : 최종 용도의 추정 및 동향 분석

제8장 폐암 액체 생검 시장 : 임상 용도의 추정 및 동향 분석

제9장 폐암 액체 생검 시장 : 제품 추정 및 동향 분석

제10장 폐암 액체 생검 시장 :지역 추정 및 동향 분석

제11장 경쟁 구도